ClinicalTrials.gg
CompletedNCT01552772Updated Oct 10, 2014Results posted

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

A Phase 1 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-10-10.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
86th of 125
60 · median 130
Started
2012
with 3 others
Phase 1
13 of 126
none open now
Registered
72nd of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 86th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 13 in phase 1, and was the 72nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study will test the safety of an aripiprazole injection in subjects with schizophrenia that are currently taking oral antipsychotic medication other than aripiprazole. Subjects in this study will receive one injection of aripiprazole and will need to stop taking their other antipsychotic medication two weeks after the injection. The study will last one month. Subjects will be required to come to a clinic for evaluations and drug and urine collection five times during the course of the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Safety
  • Tolerability
  • Schizophrenia
  • Aripiprazole
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female individuals between 18 and 64 years of age, inclusive, with a diagnosis of schizophrenia as defined by criteria.
  2. Good physical health as determined by no deviation from normal in medical history, clinical laboratory determination, ECGs, or physical examinations.
  3. Ability to provide written or consent obtained from a legally acceptable representative (as required by IRB) prior to the initiation of any protocol-required procedures.
  4. of 18 to 35 kg/m2, inclusive.
  5. Prior history of tolerating aripiprazole.
  6. Subjects must be treated with one of the following atypical oral antipsychotic medications: risperidone, olanzapine, quetiapine, ziprasidone, or paliperidone and be clinically stable, per the investigator's judgment, for 14 days prior to the administration of aripiprazole IM depot

Exclusion criteria

Exclusion Criteria:

  1. Sexually active males who will not commit to utilizing 2 of the approved methods or who will not remain abstinent during the trial and for 180 days following the last dose of trial medication, or have not had an orchidectomy or sexually active females of who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 150 days following the last dose of trial medication. Abstinence will be permitted if it is confirmed and documented at every trial visit. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injections, implant, condom or sponge with spermicide. Note: Women of childbearing potential (WOCBP) are defined as all women unless they have had an oophorectomy or hysterectomy or have been for 12 consecutive months.
  2. Subjects who have met criteria for substance abuse or dependence within the past 180 days; including alcohol and benzodiazepines, but excluding caffeine and nicotine. Subjects with a positive drug screen for cocaine or other drugs of abuse (excluding stimulants and other prescribed medications and marijuana).a
  3. Subjects likely to require prohibited concomitant therapy during the trial, and use of any CYP2D6 and inhibitors, or CYP3A4 inducers within 14 days prior to dosing and for the duration of the trial.
  4. Females who are pregnant or lactating.
  5. Subjects who had participated in any clinical trial involving a psychotropic medication within 1 month prior to enrollment; subjects who had participated in a previous IM depot trial within the last 6 months; or who had previously enrolled and received trial medication in an aripiprazole IM depot clinical trial.
  6. Any major surgery within 30 days prior to enrollment.
  7. Evidence of organ dysfunction or any deviation from normal in physical, electrocardiographic, or clinical laboratory examinations.
  8. Subjects who have a significant risk of committing suicide based on history or routine psychiatric status examination
  9. Subjects currently in an acute relapse of schizophrenia.
  10. Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  11. Subjects who were considered treatment-resistant to antipsychotic medication. (Subjects needed to have shown a previous response to an antipsychotic medication other than clozapine.)
  12. Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia.
  13. Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Aripiprazole IM Depot

    Drug: Aripiprazole IM Depot

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE).

    An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the study physician. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. TEAE stands for treatment emergent adverse events.

    Time frame: From the time the informed consent (ICF) was signed until follow-up at 30 days after the last trial visit (Day 28).

Secondary outcomes

  1. Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) for Observed Cases (OC) Data.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2, 4 and Last visit (Day 28).

  2. Change From Baseline in Total Score of PANSS for Last Observation Carried Forward (LOCF) Data.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2 and 4

  3. Change From Baseline in PANSS Positive Sub-scale Score for OC Data.

    The Positive and Negative Syndrome Scale (PANSS) consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2, 4 and Last visit (Day 28).

  4. Change From Baseline in PANSS Positive Sub-scale Score for LOCF Data.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2 and 4

  5. Change From Baseline in PANSS Negative Sub-scale Score for OC Data.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2, 4 and Last visit (Day 28).

  6. Change From Baseline in PANSS Negative Sub-scale Score for LOCF Data.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Week 1, 2 and 4

  7. Change From Baseline in Clinical Global Impression Severity (CGI-S) Score in OC Data.

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Week 1, 2, 4 and Last visit (Day 28).

  8. Change From Baseline in CGI-S Score in LOCF Data.

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Week 1, 2 and 4.

  9. Clinical Global Impression Improvement (CGI-I) Scale Score in OC Data.

    The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Week 1, 2, 4 and Last visit (Day 28).

  10. CGI-I Scale Score in LOCF Data.

    The efficacy of trial medication were rated for each participant using the Clinical Global Impression Improvement (CGI-I) scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Week 1, 2 and 4

07

Results

Posted Sep 9, 2014

Participant flow

Trial to assess the safety and tolerability of aripiprazole intramuscular (IM) depot as an adjunctive therapy in adults with schizophrenia who were stabilized on any one of the atypical oral antipsychotics other than aripiprazole. In the United States, the trial was conducted in 60 enrolled participants and were screened in 12 centres.

Participant flow — Overall Study
MilestoneAripiprazole IM Depot 400mg
Started60
Completed56
Not completed4
Withdrew: Lost to follow-up2
Withdrew: Adverse event1
Withdrew: Protocol deviation1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE).

An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the study physician. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. TEAE stands for treatment emergent adverse events.

Time frame:
From the time the informed consent (ICF) was signed until follow-up at 30 days after the last trial visit (Day 28).
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE).
ParticipantsAripiprazole IM Depot 400mg
Participants with TEAE35
Participants with serious TEAE1
SecondaryChange From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) for Observed Cases (OC) Data.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2, 4 and Last visit (Day 28).
Reported as:
Mean · Units on a scale
Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) for Observed Cases (OC) Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-2.42 ± 5.57
Week 2 (N= 56)-2.86 ± 7.98
Week 4 (N= 57)-3.82 ± 8.34
Last visit (N= 59)-3.68 ± 8.26
SecondaryChange From Baseline in Total Score of PANSS for Last Observation Carried Forward (LOCF) Data.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2 and 4
Reported as:
Mean · Units on a scale
Change From Baseline in Total Score of PANSS for Last Observation Carried Forward (LOCF) Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-2.42 ± 5.91
Week 2 (N= 59)-2.80 ± 7.83
Week 4 (N= 59)-3.68 ± 8.26
SecondaryChange From Baseline in PANSS Positive Sub-scale Score for OC Data.

The Positive and Negative Syndrome Scale (PANSS) consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2, 4 and Last visit (Day 28).
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Positive Sub-scale Score for OC Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-0.81 ± 2.45
Week 2 (N= 56)-0.79 ± 3.37
Week 4 (N= 57)-1.28 ± 2.89
Last visit (N= 59)-1.25 ± 2.84
SecondaryChange From Baseline in PANSS Positive Sub-scale Score for LOCF Data.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2 and 4
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Positive Sub-scale Score for LOCF Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-0.81 ± 2.45
Week 2 (N= 59)-0.78 ± 3.29
Week 4 (N= 59)-1.25 ± 2.84
SecondaryChange From Baseline in PANSS Negative Sub-scale Score for OC Data.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2, 4 and Last visit (Day 28).
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Negative Sub-scale Score for OC Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-0.78 ± 2.30
Week 2 (N= 56)-1.14 ± 2.88
Week 4 (N= 57)-0.96 ± 2.88
Last visit (N= 59)-0.92 ± 2.84
SecondaryChange From Baseline in PANSS Negative Sub-scale Score for LOCF Data.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Week 1, 2 and 4
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Negative Sub-scale Score for LOCF Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)-0.78 ± 2.30
Week 2 (N= 59)-1.08 ± 2.82
Week 4 (N= 59)-0.92 ± 2.84
SecondaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Score in OC Data.

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Week 1, 2, 4 and Last visit (Day 28).
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score in OC Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)0.02 ± 0.39
Week 2 (N= 56)-0.09 ± 0.35
Week 4 (N= 57)-1.14 ± 0.64
Last visit (N= 59)-1.14 ± 0.63
SecondaryChange From Baseline in CGI-S Score in LOCF Data.

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Week 1, 2 and 4.
Reported as:
Mean · Units on a scale
Change From Baseline in CGI-S Score in LOCF Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)0.02 ± 0.39
Week 2 (N= 59)-0.08 ± 0.34
Week 4 (N= 59)-0.14 ± 0.63
SecondaryClinical Global Impression Improvement (CGI-I) Scale Score in OC Data.

The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Week 1, 2, 4 and Last visit (Day 28).
Reported as:
Mean · Units on a scale
Clinical Global Impression Improvement (CGI-I) Scale Score in OC Data.
Units on a scaleAripiprazole IM Depot 400mg
Week 1 (N= 59)3.85 ± 0.45
Week 2 (N= 56)3.70 ± 0.57
Week 4 (N= 57)3.56 ± 0.78
Last visit (N= 59)3.58 ± 0.77
SecondaryCGI-I Scale Score in LOCF Data.

The efficacy of trial medication were rated for each participant using the Clinical Global Impression Improvement (CGI-I) scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition a baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Week 1, 2 and 4
Reported as:
Mean · Units on a scale
CGI-I Scale Score in LOCF Data.
Units on a scaleTotal
Week 1 (N= 59)3.85 ± 0.45
Week 2 (N= 59)3.69 ± 0.56
Week 4 (N= 59)3.58 ± 0.77

Adverse events

Collected over From the time the ICF was signed until follow-up at 30 days after the last trial visit (Day 28).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot 400mg—1/60 (1.7%)35/60 (58.3%)
Most frequent serious events
Most frequent serious events
EventAripiprazole IM Depot 400mg
Suicide AttemptPsychiatric disorders1/60
Most frequent other events
Showing 10 of 54
Most frequent other events
EventAripiprazole IM Depot 400mg
ToothacheGastrointestinal disorders4/60
Injection site painGeneral disorders4/60
FatigueGeneral disorders3/60
Blood creatine phosphokinase increasedInvestigations3/60
DystoniaNervous system disorders3/60
InsomniaPsychiatric disorders3/60
RestlessnessPsychiatric disorders3/60
Salivary hypersecretionGastrointestinal disorders2/60
Decreased appetiteMetabolism and nutrition disorders2/60
Joint stiffnessMusculoskeletal and connective tissue disorders2/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot 400mg
Mean43.2 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot 400mg
Female10 ± 33.0
Male50 ± 67.0
08

Study locations

12 sites
  • South Coast Clinical Trials
    Anaheim, California 92804, United States
  • Comprehensive Clinical Development
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
  • South Coast Clinical Trials
    Norwalk, California 90650, United States
  • CNRI-San Diego
    San Diego, California 92102, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Comprehensive Clinical Development
    Washington, District of Columbia 20016, United States
  • Accurate Clinical Trials
    Kissimmee, Florida 34741, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri 63118, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
  • Pillar Clinical Research
    Dallas, Texas 75243, United States
09

References and documents

Publications

  • Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Baker RA, Eramo A, Sanchez R, McQuade R. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013 Oct;29(10):1241-51. doi: 10.1185/03007995.2013.821973. Epub 2013 Jul 25. PubMed 23822566 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2012
First posted
Mar 13, 2012
Start
Jan 2012
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Sep 9, 2014
Last update
Oct 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01552772
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Jan 2012
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Sep 9, 2014
Last update
Oct 10, 2014

Study contacts

Stacy Wu, MD
study director · Otsuka Pharmaceutical Development and Commercialization

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion